Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results

被引：1
|
作者：
Yuan, X-J. [1 ]
Zhang, X. [1 ]
Li, Q. [2 ]
Wang, Z. [2 ]
Li, C. [3 ]
Liu, Y. [4 ]
Ge, X. [5 ]
Zhao, J. [6 ]
机构：
[1] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Paediat Hematol Oncol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Plast & Reconstruct Surg, Shanghai Peoples Hosp 9, Shanghai, Peoples R China
[3] AstraZeneca Global R&D China Co Ltd, Hematol Oncol, Shanghai, Peoples R China
[4] AstraZeneca Global R&D China Co Ltd, Biometr, Shanghai, Peoples R China
[5] AstraZeneca Global R&D China Co Ltd, Clin Safety, Shanghai, Peoples R China
[6] AstraZeneca Global R&D China Co Ltd, Clin Pharmacol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.433
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
402P
引用
收藏
页码：S1599 / S1599
页数：1
相关论文
共 50 条
  • [1] PHASE I TRIAL OF SORAFENIB IN CHILDREN WITH NEUROFIBROMATOSIS TYPE I (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Kim, A.
    Dombi, E.
    Tepas, K.
    Fox, E.
    Balis, F. M.
    Korf, B.
    Widemann, B. C.
    NEURO-ONCOLOGY, 2010, 12 (06) : II42 - II42
  • [2] Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study
    Suenobu, Souichi
    Terashima, Keita
    Akiyama, Masaharu
    Oguri, Tomoyo
    Watanabe, Asako
    Sugeno, Masatoshi
    Higashimori, Mitsuo
    So, Karen
    Nishida, Yoshihiro
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [3] Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Baldwin, Andrea
    Dombi, Eva
    Wolters, Pamela
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Fisher, Michael J.
    Kim, AeRang
    Weiss, Brian D.
    Paul, Scott M.
    Clapp, Wade
    Farrell, Kathleen
    Smith, Michaele
    Fontana, Joseph
    Brofferio, Alessandra
    Steinberg, Seth M.
    Doyle, Laurence A.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] SELUMETINIB IN CHILDREN WITH CLINICALLY ASYMPTOMATIC INOPERABLE NF1 RELATED PLEXIFORM NEUROFIBROMAS
    Glassberg, Brittany
    Gross, Andrea
    Dombi, Eva
    Baldwin, Andrea
    Whitcomb, Trish
    Fisher, Michael
    Kim, Aerang
    Weiss, Brian
    Paul, Scott
    Steinberg, Seth
    Carbonell, Amanda
    Heisey, Kara
    Therrien, Janet
    Kapustina, Oxana
    Doyle, Austin
    Smith, Malcolm
    Widemann, Brigitte
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S10 - S10
  • [5] SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Gross, Andrea
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Blakeley, Jaishri
    Whitcomb, Patricia
    Holmblad, Marielle
    Maritin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm
    Glod, John
    Steinberg, Seth
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2018, 20 : 143 - 144
  • [6] SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian D.
    Kim, AeRang
    Blakeley, Jaishri O'Neill
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm A.
    Glod, John
    Steinberg, Seth M.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] SELUMETINIB (AZD6244) HYDROGEN SULFATE, A MEK1/2 INHIBITOR, IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PNS): A PHASE I STUDY
    Fisher, Michael J.
    Marcus, Leigh
    Weiss, Brian
    Kim, AeRang
    Dombi, Eva
    Baldwin, Andrea
    Whitcomb, Patricia
    Martin, Staci
    Gillespie, Andrea
    Doyle, Austin
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2014, 16 : 129 - 129
  • [8] NEUROFIBROMATOSIS TYPE 1 PATIENTS WITH PLEXIFORM NEUROFIBROMAS TREATED WITH SELUMETINIB
    Al-Mulla, Abdulla
    Gangji, Rahaman Navaz
    Petersson, Rajanya
    Vorona, Gregory
    Snajczuk, Jordan
    Saborit, Dawn
    Rohan, Jennifer
    Wang, Zhihong
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [9] Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open-label study
    Wang, Zhichao
    Zhang, Xin
    Li, Chunyan
    Liu, Yangbo
    Ge, Xiaoyun
    Zhao, Jiajia
    Yuan, Xiaojun
    Li, Qingfeng
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (03):
  • [10] Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
    Bradford, Diana
    Whitcomb, Patricia
    Dombi, Eva
    Chen, Alice P.
    Baldwin, Andrea
    Wolters, Pamela
    Martin, Staci
    Glod, John
    Derdak, Joanne
    Coyne, Geraldine Helen O'Sullivan
    Cowen, Edward W.
    Holmblad, Marielle
    Trepel, Jane
    Wood, Bradford J.
    Paul, Scott M.
    Clapp, Wade
    Johnson, Gary L.
    Rubinstein, Larry
    Doyle, L. Austin
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345